NMS·Healthcare·$957M·#144 / 520 in Healthcare
KURA Kura Oncology, Inc.
59SPECULATIVE
CATEGORY BREAKDOWN
GROWTH40
QUALITY60
STABILITY90
VALUATION33
GOVERNANCE36
METRIC BREAKDOWN
Revenue Growth (YoY)
Year-over-year revenue growth rate
+25.2%
40
> 50% strong
Gross Margin
Revenue retained after direct costs
99.9%
100
> 50% strong
Cash Runway
Months of cash at current burn rate
28 months
90
> 24 months ideal
Debt / Equity
Total debt relative to shareholder equity
11.7%
91
< 25% strong
Price / Sales
Market cap relative to trailing revenue
13.4x
33
< 3x strong
Rule of 40
Growth rate plus operating margin
-425
0
> 40 excellent
Insider Ownership
Percentage of shares held by insiders
1.4%
11
> 20% strong
Share Dilution (12M)
Share count increase over last 12 months
+2.3%
86
< 5% ideal
SCORE HISTORY
RELATED STOCKS
COMPARE KURA WITH…
OR QUICK-COMPARE SECTOR PEERS
SCORE ALERT
Get notified when KURA's score changes by 5+ points.
DATA INFO
Last updated: Jul 1, 2026
Sources: SEC EDGAR, Financial Modeling Prep, Yahoo Finance. Not financial advice.